PSPolina A. Shtompel

Polina A. Shtompel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Polina A. Shtompel has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolution of Recurrent Myxofibrosarcoma of the Thoracic Wall at Single-Cell Resolution: A Case Report

    by Elena E. Kopantseva, Artem L. Toropov, Timur I. Fetisov, Alexander V. Ikonnikov, Alexandra V. Sentyabreva, Maxim E. Menyailo, Anastasia A. Tararykova, Polina A. Shtompel, Victoria Y. Zinovieva, Kirill I. Kirsanov, et al.

    Myxofibrosarcoma (MFS) is a common yet understudied type of soft tissue sarcoma. It is characterized by diverse cellular morphology, unusual growth patterns, and a propensity for local tumor recurrences. A 76-year-old patient underwent multiple surgical removals of MFS recurrences of the thoracic cavity and surrounding tissues with the subsequent development of metastases. Single-cell RNA sequencing was used to analyze the earlier (R7) and later (R8) MFS recurrences, with R8 removed less than a year before the detection of metastases in the lungs. The earlier MFS recurrence displays tumor clusters with multiple immunomodulatory markers (DKK1, APP, CD24, GRN) and genes involved in lipid metabolism and cell stress (DDIT3, ABCA1, ABCA10, ATF4, NEU1), combined with an anti-inflammatory TME. The later MFS recurrence shifts to a functionally less diverse phenotype, enriched in fibroblast-typical markers (POSTN, NES, COL1A1/A2), and a pro-inflammatory TME. The proliferative (MKI67, TOP2A, BUB1B) and mRNA splicing and processing (SNRNP70, SRSF2/5/11, RSRP1, LUC7L/7L3, SRRM1/2) tumor clusters are observed in both MFS recurrences, and their signatures match the previous data on primary MFS tumor populations. ScRNA-seq analysis of two subsequent MFS recurrences from one patient show a change from functionally diverse to more uniform ECM remodeling enriched tumor populations, an accompanying shift to the pro-inflammatory TME, and the presence of two common tumor clusters enriched in proliferative and mRNA-processing gene signatures.

  • Open Access

    New undifferentiated pleomorphic sarcoma cell line UPS134 for in vitro and in vivo studies

    by Polina A. Shtompel, Sofya A. Khazanova, Ekaterina S. Trapeznikova, Victoria Yu. Zinovieva, Anastasia A. Lovenger, Anastasia A. Tararykova, Beniamin Yu. Bokhyan, Natalia V. Khromova, Pavel B. Kopnin, Timur I. Fetisov, et al.

    Background. Due to the limited number of cell lines, as well as the high heterogeneity of undifferentiated pleomorphic sarcomas (UPS), the creation of new stable cell lines is relevant. Aim. Obtaining a stable cell line from a sample of UPS obtained during surgery to model carcinogenesis processes in vitro and in vivo. Materials and methods. Cells were isolated from a tumor sample from a patient diagnosed with UPS. After passage 40 and stable growth, the proliferation rate, cell morphology, and growth ability in 3D culture conditions were assessed. To assess tumorigenicity, the cell suspension was injected into BALB / c nu / nu athymic mice. On the 15th day of the experiment, the tumor was removed, its volume was measured, and it was examined histologically. Using short tandem repeat (STR) analysis, the cells of the resulting line were examined for the presence of human cell markers and their uniqueness. The chemosensitivity of the cells was assessed using the resazurin test. Results. Stable growth and formation of spheroids under 3D culturing conditions were demonstrated for the cell culture. All mice inoculated with the UPS134 cell suspension showed tumor growth, and by day 14 of the experiment its average size was 28,7 mm3. Histologically, the tumor is similar in morphology to UPS, except for a smaller amount of myxoid and less polymorphism. The cells of the obtained line were shown to contain all analyzed genetic markers of human cells, and also that the STR data of the obtained line did not coincide with the STR of other lines. For doxorubicin, gemcitabine and docetaxel, IC50 (inhibitory concentration) were determined to be 15, 6.5 and 10 % of the plasma peak concentration, respectively. Conclusions. We obtained a new cell line UPS134, which can be further used to study the pathogenesis of UPS, as well as in preclinical studies of new antitumor agents in vitro and in vivo.

  • Open Access

    Single-Cell RNA Sequencing Reveals the Cellular and Molecular Differences Between Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma

    by Timur I. Fetisov, Alexander V. Ikonnikov, Elena E. Kopantseva, Polina A. Shtompel, Sofya A. Khazanova, Ekaterina S. Trapeznikova, Victoria Y. Zinovieva, Svetlana N. Zuevskaya, Anastasia A. Tararykova, Beniamin Yu. Bokhyan, et al.

    Objective: Myxofibrosarcoma (MXF) and undifferentiated pleomorphic sarcoma (UPS) are common and aggressive subtypes of cancer differing by clinical characteristics and prognosis; however, their differential diagnosis is difficult. Elucidation of cellular and transcriptomic discrepancies between these diseases that could improve their identification was the aim of our study. Methods: We applied single-cell RNA sequencing to compare MXF and UPS by tumor cell clusters and cell–cell ligand–receptor interactions, using five tumor samples of both subtypes. Results: We identify nine major cell types in all tumors analyzed. Any significant differences in their proportions between MXF and UPS were not found. Further reclusterization of lymphoid cells showed that cytotoxic CD8+ T cell proportion was higher in the MXF samples. In UPS cancer cells, the pathways maintaining extracellular matrix components (including collagens, proteoglycans, and other proteins) were highly active, while MXF cells were characterized by high activity of growth factors and angiogenesis pathways. The ligand–receptor interactions between cancer cells and the microenvironment differed significantly between MXF and UPS. In UPS, CD80 of dendritic cells and macrophages prominently interacted with T cell co-inhibitory CTLA-4 receptors, whereas the activating CD80-CD28 interaction was predominant in MXF. Moreover, in UPS, CD44 and integrins of cytotoxic CD8+ T cells prominently interacted with COL1A1/2, while in MXF CD44, interaction with FN1, COL6A1, and LAMC1 prevailed. Conclusions: Differences were identified between UPS and MFS in the composition of lymphoid cell populations and in the intercellular interactions. This proposes deeper understanding of the biological differences between these sarcoma subtypes and may be important for the development of new therapeutic approaches, although further validation of the findings is required.


  • Open Access

    Anticancer Plant Secondary Metabolites Evicting Linker Histone H1.2 from Chromatin Activate Type I Interferon Signaling

    by Olga Vlasova, Irina Antonova, Khamis Magomedova, Alena Osipova, Polina Shtompel, Anna Borunova, Tatiana Zabotina, Gennady Belitsky, Irina Budunova, Albert Jordan, et al.

    Previously we discovered that among 15 DNA-binding plant secondary metabolites (PSMs) possessing anticancer activity, 11 compounds cause depletion of the chromatin-bound linker histones H1.2 and/or H1.4. Chromatin remodeling or multiH1 knocking-down is known to promote the upregulation of repetitive elements, ultimately triggering an interferon (IFN) response. Herein, using HeLa cells and applying fluorescent reporter assay with flow cytometry, immunofluorescence staining and quantitative RT-PCR, we studied effects of PSMs both evicting linker histones from chromatin and not influencing their location in nucleus. We found that (1) 8 PSMs, evicting linker histone H1.2 from chromatin, activated significantly the type I IFN signaling pathway and out of these compounds resveratrol, berberine, genistein, delphinidin, naringenin and curcumin also caused LINE1 expression. Fisetin and quercetin, which also induced linker histone H1.2 eviction from chromatin, significantly activated only type I IFN signaling, but not LINE1 expression; (2) curcumin, sanguinarine and kaempferol, causing significant depletion of the chromatin-bound linker histone H1.4 but not significantly influencing H1.2 presence in chromatin, activate type I IFN signaling less intensively without any changes in LINE1 expression; (3) four PSMs, which did not cause linker histone eviction, displayed neither IFN signaling activation nor enhancement of LINE1 expression. Thus, we have shown for the first time that chromatin destabilization observed by depletion of chromatin-bound linker histone H1.2 caused by anticancer DNA-binding PSMs is accompanied by enhancement of type I IFN signaling, and that LINE1 expression often impacts this activation.


  • Open Access

    Changes in the expression of genes that regulate apoptosis as a factor in the development of chemoresistance in soft tissue sarcoma

    by T. I. Fetisov, S. A. Khazanova, P. A. Shtompel, E. S. Trapeznikova, A. A. Tararykova, V. Yu. Zinovyeva, V. I. Marshall, A. A. Lowenger, I. S. Kupaeva, D. V. Rogozhin, et al.

    Introduction. The active use of highly toxic chemotherapy in the treatment of soft tissue sarcomas determines the need to search for criteria and markers of chemoresistance of patients to the therapy.Aim. To study the connection between tumor cell resistance to chemotherapy and expression levels of apoptosis-regulating proteins (PUMA, PMAIP-1, PIDD-1, AIFM-2, Bax, GADD45a) in primary cultures of soft tissue sarcomas.Materials and methods. Primary cultures of soft tissue sarcomas were obtained using enzymatic digestion, cell death was evaluated using resazurine assay. Gene expression was measured using real-time polymerase chain reaction, protein levels using immunoblotting assay.Results. 73 primary cultures of soft tissue sarcomas were obtained, for which chemosensitivity to doxorubicin, ifosfamide, docetaxel, gemcitabine, pazopanib and their combinations was determined using a resazurin cytotoxicity test. Associations of AIFM-2 gene expression with resistance to pazopanib, doxorubicin and its combination with ifosfamide were found in liposarcoma, synovial and undifferentiated pleomorphic sarcomas. In addition, associations between the expression of the Bax, PUMA, PMAIP-1, GADD45a and PIDD-1 genes and resistance to the studied drugs in various nosological subgroups of sarcomas were identified. When studying the amount of protein, it was revealed that undifferentiated pleomorphic and synovial sarcomas with a low content of GADD45a are more resistant to the studied drugs. Liposarcomas with high Bax expression are more resistant to docetaxel and gemcitabine, while synovial sarcomas with high Bax expression are more sensitive to doxorubicin and ifosfamide.Conclusion. The data obtained indicate a relationship between the activity of the studied genes-regulators of apoptosis and resistance to drugs used in the treatment of soft tissue sarcomas.

  • Open Access

    Interferon Signaling Activation and LINE1 Expression under Influence of Anticancer Plant Secondary Metabolites

    by Olga Vlasova, Irina Antonova, Khamis Magomedova, Alena Osipova, Polina Shtompel, Anna Borunova, Tatyana Zabotina, Gennady Belitsky, Irina Budunova, Albert Jordan, et al.

    Previously we discovered that among 15 DNA-binding plant secondary metabolites (PSMs) possessing anticancer activity, 11 compounds cause depletion of the linker histones H1.2 and/or H1.4 from chromatin fraction. Chromatin remodeling or multiH1 knocking-down is known to promote the upregulation of repetitive elements, ultimately triggering an interferon response. Herein, using HeLa cells and applying fluorescent reporter assay with flow cytometry and quantitave RT-PCR, we found that among PSMs depleting linker histones, 8 compounds significantly activate type I interferon signaling pathway. Out of these compounds resveratrol, berberine, genistein, delphinidin, naringenin and curcumin also caused LINE1 expression detected by quantitate RT-PCR and by immunefluorescent staining analysis of ORF1 LINE1 and γ-H2AX. Fisetin and quercetin, which also induced linker histone depletion, significantly activated only type I interferon signaling, but not LINE1 expression. Curcumin, sanguinarine and kaempferol, causing depletion of the linker histone H1.4 more intensively respectively to H1.2, activate interferon signaling less intensively without any changes of LINE1 expression. For 4 PSMs, which did not cause linker histone depletion, we did not observe effects of interest. Thus, we have shown for the first time that activation of type I interferon signaling accompanies chromatin remodeling caused by PSMs, and LINE1 expression often impacts this activation.

  • Open Access

    Mechanisms of sexual dimorphism in the pathogenesis of sarcomas

    by G. A. Belitsky, T. I. Fetisov, P. A. Shtompel, E. A. Lesovaya, B. Yu. Bokhyan, M. G. Yakubovskaya, K. I. Kirsanov

    Sarcomas of non-genital organs affect women 1.5–3 times less often than men. The mechanism of such dimorphism is studied at various levels, mainly in the field of influence on the pathogenesis of sex hormones and their receptors, the effect of which is significantly related to the histogenesis of the tumor, its localization, the mechanism of malignant transformation and the stage of progression. Sex hormone receptors are often found in the early stages of tumor development and are lost during progression. At the same time, the expression of the same receptors in tumors of different histogenesis sometimes correlates with the opposite prognosis of the disease and sensitivity to hormonal therapy. For example, in uterine leiomyosarcomas, the expression of estrogen and androgen receptors correlates with a better prognosis and greater effectiveness of therapy, and in osteo- and fibrosarcomas, vice versa. Estrogens stimulate proliferation of osteosarcoma cells, and androgens that of rhabdomyosarcoma and small round cell tumor, which growth is inhibited by antiandrogens used in the treatment of prostate cancer. In this regard, when trying to include a hormonal component in a therapeutic complex, an individual study of the hormonal sensitivity of the tumor is necessary. One of the methodological approaches to this could be testing a culture of tumor cells from surgical material for sensitivity to agonists/antagonists of hormonal receptors separately and in combination with chemotherapy drugs.

  • Open Access

    Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy

    by Timur I. Fetisov, Sofya A. Khazanova, Polina A. Shtompel, Ekaterina S. Trapeznikova, Victoria Y. Zinovieva, Valeria I. Marshall, Anastasia A. Lovenger, Dmitriy V. Rogozhin, Tararykova A. Anastasia, Beniamin Yu. Bokhyan, et al.

    Treatment of highly malignant soft tissue sarcomas (STSs) requires multicomponent therapy including surgery, radiotherapy, and chemotherapy. Despite the advancements in targeted cancer therapies, cytostatic drug combinations remain the gold standard for STS chemotherapy. The lack of algorithms for personalized selection of STS chemotherapy leads to unhelpful treatment of chemoresistant tumors, causing severe side effects in patients. The goal of our study is to assess the applicability of in vitro chemosensitivity/resistance assays (CSRAs) in predicting STS chemoresistance. Primary cell cultures were obtained from 148 surgery samples using enzymatic and mechanical disaggregation. CSRA was performed using resazurin-based metabolic activity measurement in cells cultured with doxorubicin, ifosfamide, their combination and docetaxel, gemcitabine, and also their combination for 7 days. Both the clinical data of patients and the CSRA results demonstrated a higher resistance of some cancer histotypes to specific drugs and their combinations. The correlation between the CSRA results for doxorubicin and ifosfamide and clinical responses to the combination chemotherapy with these drugs was demonstrated via Spearman rank order correlation. Statistically significant differences in recurrence-free survival were also shown for the groups of patients formed, according to the CSRA results. Thus, CSRAs may help both practicing physicians to avoid harmful and useless treatment, and researchers to study new resistance markers and to develop new STS drugs.